



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

## ***Table of Contents and List of Tables***

Copyright 2012 VENTURE PLANNING GROUP  
This material is confidential for use by our clients only  
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients [www.VPGcorp.com](http://www.VPGcorp.com)

VPG Market Research Reports [www.VPGMarketResearch.com](http://www.VPGMarketResearch.com)

VPG Partner Reports [www.Research-Store.com/VPG](http://www.Research-Store.com/VPG)

**VENTURE PLANNING GROUP** 545 Eighth Avenue, Suite 401 New York, NY 10018  
Phone + 1 212 564 2838 Fax + 1 212 564 8133 [info@vpgcorp.com](mailto:info@vpgcorp.com)

## Table of Contents

### Introduction

#### Worldwide Market And Technology Overview

##### **A. DNA Sequencing**

1. *Introduction*
2. *Sequencing Methods*
3. *Autoradiography*
4. *The Human Genome Project*
5. *Sequencing Automation*
6. *Image Scanners*
7. *Fluorescent Detection*
8. *Gene Profiling*
9. *Gene Expression*
10. *Polymorphism Screening*
11. *Protein Interaction Networks*

##### **B. DNA And RNA Probe Technology**

1. *Basic Principles*
2. *Probe Preparation*
3. *The DNA Probe Test*
  - a. *Sample Preparation*
  - b. *Hybridization*
  - c. *Separation*
  - d. *Detection/Measurement*
4. *Test Formats*
  - a. *Filter Hybridization*
  - b. *Southern Blot*
  - c. *Northern Blot*
  - d. *In Situ Hybridization*
  - e. *Others*
5. *Labeling Techniques*
6. *Amplification Methods*
  - o *Polymerase Chain Reaction*
    - *Temperature Cyclers*

**Table of Contents** (continued)

- *PCR Variations*
    - \* *Immuno-PCR*
    - \* *QC-PCR*
    - \* *DAP-PCR*
  - o *Strand Displacement Activation*
  - o *TMA*
  - o *Ligase Chain Reaction*
  - o *Branched DNA*
    - *Hybridization Protection Assay*
  - o *Nucleic-Acid Sequence-Based Amplification*
  - o *Self-Sustained Sequence Replicase*
  - o *Others*
    - *Ampliprobe*
    - *CAR*
    - *CAS*
    - *CPT*
    - *Dendritic Polymer Technology*
    - *ISO-CR*
    - *LAT*
    - *Probe Networks*
    - *RAMP*
    - *Repair Chain Reaction*
    - *Rolling Circles*
    - *Sequence Independent Gene Amplification*
    - *Sequence Initiation Reaction*
    - *SISPA*
    - *Solid Phase Amplification*
- C. Detection Technologies**
- 1. Radioactive Methods**
    - a. *Overview*
    - b. *Major Isotopes*
      - o *P-32*
      - o *S-35*
      - o *H-3*
      - o *I-125*
  - 2. Non-Isotopic Methods**
    - a. *Enzymatic Labels*
    - b. *Chemical Labeling*
      - o *Indirect Chemical Labeling*
      - o *Direct Chemical Labeling*

**Table of Contents (continued)**

- c. *Fluorescence*
    - d. *Chemiluminescence*
    - e. *Electrical Conductivity*
- D. *Instrumentation Review*
  - 1. *Abbott LCx*
  - 2. *Beckman Coulter/Biomek FK*
  - 3. *Becton Dickinson SDA*
  - 4. *Bio-Rad GeneScope*
  - 5. *Gen-Probe Tigris*
  - 6. *Roche Cobas Amplicor*
  - 7. *Tecan LS Series*
- E. *Biochips: Genosensors, Microarrays, and Labs-on-the-Chip*
  - *Liquid Transportation and Mixing*
  - *Separation*
  - *Reaction*
  - *Detection*
- F. *Pharmacogenomics*
- G. *Major Applications*
  - 1. *Microbiology/Infectious Diseases*
    - a. *Overview*
    - b. *Major Infectious Diseases*
      - \* *AIDS*
        - o *Structure and Composition*
        - o *Classification*
        - o *AIDS Origins*
        - o *Animal Lentivirus Systems*
        - o *Virus Receptors*
        - o *HIV Infections in Humans*
          - *Pathogenesis and Pathology*
        - o *CD4T Lymphocytes and Memory Cells*
        - o *Monocytes and Macrophages*
        - o *Lymphoid Organs*
        - o *Neural Cells*
        - o *Viral Coinfections*
          - *Clinical Findings*
        - o *Plasma Viral Load*

**Table of Contents (continued)**

- *Pediatric AIDS*
  - *Neurologic Disease*
  - *Opportunistic Infections*
  - *Cancer*
- *Immunity*
  - *Virus Isolation*
  - *Serology*
  - *Viral Nucleic Acid/Antigen Detection*
- *Epidemiology*
  - *Worldwide Spread of AIDS*
  - *United States*
  - *Routes of Transmission*
- *DNA Probes*
  - *Overview*
  - *Quantitative PCR*
  - *In Situ PCR*
  - *Needed Improvements*
- *Viral Load/Drug Resistance Testing*
- *Genotype and Phenotype Testing*
- *Blood Banking Considerations*
- \* *Adenovirus*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
  - *Adeno-Associated Viruses (AAV)*
- \* *Anthrax/Bacillus Anthracis*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Babesiosis*
  - *Background*
- \* *BEA and Other Bartonella Diseases*
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* *Chagas Disease*
  - *Background*

**Table of Contents (continued)**

- \* **Campylobacter**
  - **Background**
  - **Diagnostic Tests**
    - *Culture Identification*
  - **Vaccines and Drugs**
- \* **Chlamydia**
  - **Background**
    - *Chlamydia psittaci*
    - *Chlamydia pneumoniae*
    - *Chlamydia trachomatis*
  - **Diagnostic Tests**
  - **Vaccines and Drugs**
- \* **Creutzfeldt-Jakob's Disease**
  - **Background**
  - **Blood Transmission**
  - **Diagnostic Tests**
  - **Major Commercial and Academic Players**
    - *Bayer*
    - *Disease Sciences/Bio Tec Global*
    - *Imperial College School of Medicine*
    - *Ortho-Clinical Diagnostics*
    - *Pall*
    - *ProMetic Life Sciences*
    - *Proteome Sciences/Idexx*
    - *Q-One Biotech*
    - *Serono*
    - *U.S. Agricultural Research Service*
  - **Drugs**
  - **Vaccines**
- \* **Cytomegalovirus**
  - **Background**
    - *Chorioretinitis*
    - *Gastrointestinal*
    - *Central Nervous System Disease*
  - **Diagnostic Tests**
  - **Vaccines and Drugs**
- \* **Ebola Virus**
  - **Background**
    - *Epidemiology*
    - *Clinical Syndromes*

**Table of Contents (continued)**

- *Diagnostic Tests*
- *Vaccines and Drugs*
- \* ***EchoVirus***
  - *Background*
    - *Acute Aseptic Meningitis*
    - *Encephalitis*
    - *Exanthems*
    - *Respiratory Disease*
    - *Myopericarditis*
    - *Neonatal Infections*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* ***Encephalitis***
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* ***Enteroviruses***
  - *Background*
  - *Diagnostic Tests*
    - *Viral Isolation and Identification*
    - *Antibody Tests*
  - *Vaccines and Drugs*
- \* ***Epstein-Barr Virus***
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* ***Gonorrhea***
  - *Background*
  - *Diagnostic Tests*
  - *Vaccines and Drugs*
- \* ***Hepatitis***
  - *Hepatitis A*
  - *Hepatitis B*
    - *Structure and Composition*
    - *Replication*
  - *Hepatitis C*
  - *Hepatitis D (Delta)*
  - *Hepatitis E*
  - *Hepatitis G*
  - *Hepatitis Infections Pathology*
  - *Clinical Findings*
  - *Laboratory Tests*

**Table of Contents (continued)**

- *Hepatitis A*
- *Hepatitis B*
- *Hepatitis C*
- *Hepatitis D*
- *Hepatitis E*
- o *Virus-Host Immune Reactions*
- o *Epidemiology*
  - *Hepatitis A*
  - *Hepatitis B*
  - *Hepatitis C*
  - *Hepatitis D (Delta)*
- o *Vaccines and Drugs*
- \* *Herpes Simplex Virus*
  - o *Background*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- \* *Legionella*
  - o *Background*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- \* *Lyme Disease*
  - o *Background*
    - *Clinical Description*
    - *Clinical Case Definition*
    - *Laboratory Criteria for Diagnosis*
    - *Case Classification*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- \* *Malaria*
- \* *Mycoplasma*
  - o *Background*
    - *Ureaplasma Urealyticum & Mycoplasma Hominis*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- \* *Papillomaviruses/HPV*
  - o *Background*
    - *HPV in Cancer*
    - *Cervical Neoplasm*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*

**Table of Contents (continued)**

- *Prevention*
- \* **Parvovirus B19**
  - o *Background*
    - *Microbiology*
    - *Epidemiology*
    - *Clinical Syndromes*
      - *Erythema Infectiosum (Slapped Cheek)*
      - *Adult Polyarthropathy*
      - *Transient Aplastic Crisis*
      - *Transient Pancytopenia*
      - *Red Cell Aplasia in Immunocompromised*
      - *Perinatal Infections*
    - o *Diagnostic Test*
    - o *Vaccines and Drugs*
  - \* **Pneumonia**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*
  - \* **Polyomaviruses**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*
  - \* **Salmonellosis**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*
  - \* **Shigellosis**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*
  - \* **Streptococci**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*
      - *Group A Streptococci*
      - *Group B Streptococci*
  - \* **Toxoplasmosis**
    - o *Background*
    - o *Diagnostic Tests*
    - o *Vaccines and Drugs*

**Table of Contents (continued)**

- \* **Tuberculosis**
  - o *Background*
  - o *Diagnostic Tests*
    - *Microscopic Characteristics*
    - *Cultural Characteristics*
    - *Skin Tests*
    - *MDRTB*
  - o *Vaccines and Drugs*
- \* **West Nile Virus**
  - o *Background*
    - *Clinical Syndromes*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- \* **Yersinia**
  - o *Background*
  - o *Diagnostic Tests*
  - o *Vaccines and Drugs*
- c. *Antibiotic Susceptibility*
- 2. *Cancer Testing*
  - a. *Overview*
  - b. *Major Cancer Types*
    - \* *Prostate*
    - \* *Lung*
    - \* *Colon and Rectum*
    - \* *Breast*
    - \* *Skin*
    - \* *Uterine*
    - \* *Leukemia*
    - \* *Oral*
  - c. *Oncogenes*
    - o *Abl/abl-bcr*
    - o *AIB1*
    - o *BCL-2*
    - o *BRCA1*
    - o *CD44*
    - o *C-fos*
    - o *C-myb*
    - o *C-myc*
    - o *CYP17*
    - o *Erb-B*
    - o *HPC1*

**Table of Contents (continued)**

- o *N-myc*
  - o *P40*
  - o *P51*
  - o *P53*
  - o *PIK3CA*
  - o *PTI-1*
  - o *Ras*
  - o *Reg*
  - o *Sis*
  - o *Src*
3. *Genetic Diseases*
- a. *Overview*
  - b. *Nucleic Acid Amplification*
  - c. *Chromosome Imaging*
  - d. *Genomics Technologies*
  - e. *Proteomics Technologies*
  - f. *Current Pharmacogenomic Tests*
  - g. *Future Pharmacogenomic Testing*
  - h. *Major Diseases*
    - \* *Achondroplasia*
    - \* *Autosomal Dominant Polycystic Kidney Disease*
    - \* *Cancer*
    - \* *Cosmetogenomics*
    - \* *Cystic Fibrosis*
    - \* *Down's Syndrome*
    - \* *Duchenne and Becker Muscular Dystrophy*
      - \* *Factor V (Leiden)*
      - \* *Factor IX Deficiency*
      - \* *Fragile X Syndrome*
      - \* *Heart Disease*
      - \* *Hemochromatosis*
      - \* *Hemophilia*
      - \* *Huntington's Disease*
      - \* *Maternal-Fetal Incompatibility*
      - \* *Multiple Endocrine Neoplasia*
      - \* *Phenylketonuria (PKU)*
      - \* *Polycystic Kidney Disease (PKD)*
      - \* *Prenatal Screening*
      - \* *Retinitis Pigmentosa*
      - \* *Retinoblastoma*
      - \* *Sickle Cell Anemia*

Table of Contents (continued)

- \* *Spinal Muscular Atrophy*
- \* *Vitamin B12 Metabolism*
- i. *Social Issues and Concerns*
- 4. *Forensic Testing*
  - a. *Overview*
  - b. *Multilocus and Single Locus Probes*
    - \* *Multilocus Probes*
    - \* *Single Locus Probes*
    - \* *PCR and RFLP*
  - c. *The FBI*
  - d. *DNA Profile Data Banks*
    - \* *U.S.A.*
    - \* *U.K.*
  - e. *Judicial Implementation*
  - f. *Major Crime Categories*
  - g. *Factors Contributing to the DNA Probe Market Expansion*
    - \* *Technology Availability*
    - \* *Use of Hair as Evidence*
  - h. *Wildlife Forensics*
- 5. *Paternity Testing/HLA Typing*
- 6. *Other Applications*
  - a. *Disease Susceptibility Testing*
  - b. *Cardiovascular Diseases*
  - c. *Diabetes*
  - d. *Alzheimer's Disease*
  - e. *Periodontal Disease*
  - f. *Plasma Purification*
  - g. *Organ Transplantation*
  - h. *Water Contamination*
  - i. *Other*
- H. *Competing/complementing Technologies*
  - 1. *Monoclonal Antibodies/Immunoassays*
  - 2. *RNA Probes*
  - 3. *Two-Dimensional Electrophoresis*
  - 4. *Flow Cytometry*

**Table of Contents (continued)**

**France**

- A. Executive Summary**
- B. Business Environment**
- C. Market Structure**
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares**

**Germany**

- A. Executive Summary**
- B. Business Environment**
- C. Market Structure**
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares**

**Italy**

- A. Executive Summary**
- B. Business Environment**
- C. Market Structure**
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares**

**Spain**

- A. Executive Summary**
- B. Business Environment**
- C. Market Structure**
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares**

**U.K.**

- A. Executive Summary**
- B. Business Environment**
- C. Market Structure**
- D. Market Size, Growth And Major Suppliers' Sales And Market Shares**

**Major Product Development Opportunities**

- A. Instrumentation**
- B. Reagent Kits and Test Systems/panels**
- C. Computers, Software and Automation**
- D. Auxiliary Products**

**Table of Contents (continued)**

**Design Criteria For Decentralized Testing Products**

**Alternative Market Penetration Strategies**

- A. Internal Development**
- B. Collaborative Arrangements**
- C. University Contracts**
- D. Distribution Strategies For Decentralized Testing Markets**
  - 1. Marketing Approaches**
  - 2. Product Complexity**
  - 3. Customer Preference**
  - 4. Established Suppliers**
  - 5. Emerging Suppliers**
  - 6. Major Types Of Distributors**
  - 7. Market Segmentation**

**Potential Market Entry Barriers And Risks**

- A. Market Maturity**
- B. Cost Containment**
- C. Competition**
- D. Technological Edge And Limitations**
- E. Patent Protection**
- F. Regulatory Constraints**
- G. Decentralized Testing Market Challenges**

**Competitive Profiles**

- **Abbott**
- **Affymetrix**
- **Agilent**
- **Applied Gene Technologies**
- **Arca**
- **Beckman Coulter/Danaher**
- **Becton Dickinson**
- **Biokit**

**Table of Contents** (continued)

- *BioMerieux*
- *Bio-Rad*
- *Biostest*
- *Caliper*
- *Cepheid*
- *Decode*
- *Diadexus*
- *Eiken*
- *Enzo*
- *Exact Sciences*
- *Fujirebio*
- *Gen-Probe*
- *Hologic*
- *Illumina*
- *Innogenetics/Solvay*
- *Kreatech*
- *Li-Cor Biosciences*
- *Life Technologies*
- *Monogram Biosciences*
- *Myriad Genetics*
- *Nanogen/Elitech*
- *Novartis*
- *Orchid CellMark*
- *Ortho-Clinical Diagnostics*
- *Proteome Sciences*
- *Qiagen*
- *Roche*
- *Scienion*
- *Sequenom*
- *Shimadzu*
- *Siemens*
- *Sierra Molecular*
- *Takara Bio*
- *Tecan Group*

**Table of Contents (continued)**

**Appendices**

***Appendix I: Major Universities and Research Centers***

***Developing Molecular Diagnostic Technology***

***Appendix II: Glossary of Terms***

***Appendix III: Currency Exchange Rates***

List of Tables

*Major Companies Developing or Marketing AIDS Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Adenovirus Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Campylobacter Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Chlamydia Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing CMV Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing EBV Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Hepatitis Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Herpes Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Legionella Molecular Diagnostic And Other Direct Identification Tests*

List of Tables (continued)

*Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Papilloma Virus Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Pneumonia Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Salmonella Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Shigella Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Streptococci Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic And Other Direct Identification Tests*

*Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic And Other Direct Identification Tests*

*Oncogenes Potential Application in Cancer Diagnosis*

*Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests*

List of Tables (continued)

*Major Companies Developing or Marketing Molecular Diagnostic Test For Genetic Diseases*

*Summary Table France, Molecular Diagnostic Test Volume And Sales Forecast by Major Application*

*France, Laboratories Performing DNA Sequencing By Market Segment*

*France, Molecular Diagnostics Market Potential Laboratory Universe by Market Segment*

*France, Molecular Diagnostic Test Volume Forecast By Major Application*

*France, Major Infectious Disease Molecular Diagnostics Test Volume Forecast*

*France, Infectious Disease Screening NAT Volume Forecast*

*France, Molecular Diagnostics Market Forecast By Major Application*

*France, Infectious Disease Screening NAT Reagent Market Forecast by Test*

*France, Molecular Diagnostics Market By Major Supplier*

*France, HIV/Hepatitis NAT Market Reagent Sales By Major Supplier*

*Summary Table Germany, Molecular Diagnostics Test Volume And Sales Forecast by Major Application*

*Germany, Laboratories Performing DNA Sequencing by Market Segment*

List of Tables (continued)

*Germany, Molecular Diagnostics Market  
Potential Laboratory Universe by Market Segment*

*Germany, Molecular Diagnostics Test Volume Forecast  
By Major Application*

*Germany, Major Infectious Disease Molecular  
Diagnostics Test Volume Forecast*

*Germany, Infectious Disease Screening  
NAT Volume Forecast*

*Germany, Molecular Diagnostics Market Forecast  
By Major Application*

*Germany, Infectious Disease Screening  
NAT Reagent Market Forecast by Test*

*Germany, Molecular Diagnostics  
Market by Major Supplier*

*Germany, HIV/Hepatitis NAT Market Reagent  
Sales by Major Supplier*

*Summary Table Italy, Molecular Diagnostics Test Volume  
And Sales Forecast by Major Application*

*Italy, Laboratories Performing  
DNA Sequencing by Market Segment*

*Italy, Molecular Diagnostics Market Potential  
Laboratory Universe by Market Segment*

*Italy, Molecular Diagnostics Test Volume Forecast  
By Major Application*

*Italy, Major Infectious Disease Molecular  
Diagnostics Test Volume Forecast*

**List of Tables** (continued)

*Italy, Infectious Disease Screening  
NAT Volume Forecast*

*Italy, Molecular Diagnostics Market Forecast  
By Major Application*

*Italy, Infectious Disease Screening  
Nat Reagent Market Forecast by Test*

*Italy, Molecular Diagnostics Market  
By Major Supplier*

*Italy, HIV/Hepatitis NAT Market  
By Major Supplier*

*Summary Table Spain, Molecular Diagnostics Test Volume  
And Sales Forecast by Major Application*

*Spain, Laboratories Performing  
DNA Sequencing by Market Segment*

*Spain, Molecular Diagnostics Market, Potential  
Laboratory Universe by Market Segment*

*Spain, Molecular Diagnostics Test Volume  
Forecast by Major Application*

*Spain, Major Infectious Disease Molecular  
Diagnostics Test Volume Forecast*

*Spain, Infectious Disease Screening  
NAT Volume Forecast*

*Spain, Molecular Diagnostics Market Forecast  
By Major Application*

*Spain, Infectious Disease Screening Nat  
Reagent Market Forecast by Test*

List of Tables (continued)

*Spain, Molecular Diagnostics Market  
By Major Supplier*

*Spain, HIV/Hepatitis NAT Market Reagent  
Sales by Major Supplier*

*Summary Table U.K., Molecular Diagnostics Test Volume  
And Sales Forecast by Major Application*

*U.K., Laboratories Performing  
Dna Sequencing by Market Segment*

*U.K., Molecular Diagnostics Market Potential  
Laboratory Universe by Market Segment*

*U.K., Molecular Diagnostics Test Volume Forecast  
By Major Application*

*U.K., Major Infectious Disease Molecular  
Diagnostics Test Volume Forecast*

*U.K., Infectious Disease Screening  
NAT Volume Forecast*

*U.K., Molecular Diagnostics Market Forecast  
By Major Application*

*U.K., Infectious Disease Screening NAT Reagent  
Market Forecast by Test*

*U.K., Molecular Diagnostics Market by Major Supplier*